Comparing Upadacitinib and Filgotinib for Ulcerative Colitis
Author Information
Author(s): Vuyyuru Sudheer Kumar, Yuan Yuhong, Jairath Vipul
Primary Institution: Western University London Canada
Hypothesis
Is the evidence sufficient to inform treatment decisions between upadacitinib and filgotinib?
Conclusion
Upadacitinib may have superior efficacy compared to filgotinib, especially in patients with prior biologic exposure, despite higher rates of adverse events.
Supporting Evidence
- Upadacitinib was associated with significantly higher risk of clinical response and clinical remission compared to filgotinib.
- Real-world studies have shown similar efficacy between upadacitinib and tofacitinib.
- Adverse events were more common with upadacitinib, including skin rash and acne.
Takeaway
This study looks at two medicines for treating a gut disease and finds that one might work better than the other, but it also causes more side effects.
Methodology
A retrospective, real-world observational study with multivariable analysis and propensity score matching.
Potential Biases
Selection bias and residual confounding may affect the results due to the nature of the study design.
Limitations
The study's retrospective design and relatively small sample size may limit the findings.
Participant Demographics
Patients treated at three tertiary care centers in Japan, median follow-up of approximately 6 months.
Statistical Information
Confidence Interval
95% CI [1.09–1.80] for clinical response; 95% CI [1.16–2.05] for clinical remission.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website